AstraZeneca continues to ramp up COVID-19 vaccine production with new CMO partnership

pharmafile | June 25, 2020 | News story | Manufacturing and Production AstraZeneca, COVID-19, Vaccine 

AstraZeneca has continued to build its manufacturing capacity to deliver its COVID-19 vaccine candidate, developed in partnership with the University of Oxford and currently being tested in human trials across a number of trials across the UK, with its latest partnership signed with Scottish firm Symbiosis Pharmaceutical Services.

Under the agreement, the contract manufacturing organisation will offer “fast-track” to its sterile vaccine drug product manufacturing capacity in order to supply doses of the vaccine to clinical trial sites for further research.

It’s the latest in a line of deals sealed by AZ in the past months, after securing funding from the US and UK Governments in exchange for securing reserves of the vaccine. The company plans to manufacture two billion doses by 2021.

“Our team is immensely proud to be able to make a highly meaningful contribution to the global fight against COVID-19 and the urgent efforts to develop a successful vaccine” commented Colin MacKay, founder and CEO of Symbiosis. “With many years of direct experience manufacturing medicines and vaccines of this nature for clinical trials and commercial markets, we are delighted to be able to leverage our expertise and competitive strengths to accelerate the development of this vaccine for AstraZeneca and to add value to the project.”

Matt Fellows

Related Content

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …


FDA committee votes in favour of Pfizer’s RSV vaccine for maternal immunisation

Pfizer has announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) from the …

Latest content